Influence of the HER receptor ligand system on sensitivity to cetuximab and trastuzumab in gastric cancer cell lines by unknown
1 3
J Cancer Res Clin Oncol (2017) 143:573–600
DOI 10.1007/s00432-016-2308-z
ORIGINAL ARTICLE – CANCER RESEARCH
Influence of the HER receptor ligand system on sensitivity 
to cetuximab and trastuzumab in gastric cancer cell lines
Julia Kneissl1 · Anja Hartmann1 · Nicole Pfarr1 · Franziska Erlmeier1 · 
Thomas Lorber2 · Simone Keller1 · Gwen Zwingenberger1 · Wilko Weichert1 · 
Birgit Luber1  
Received: 8 September 2016 / Accepted: 17 November 2016 / Published online: 8 December 2016 
© The Author(s) 2016. This article is published with open access at Springerlink.com
Exogenous HB-EGF was effective in rescuing sensitive cell 
lines from inhibition of cell proliferation by both, cetuxi-
mab and trastuzumab.
Conclusions Our data indicate that HB-EGF may be a use-
ful marker for the prediction of trastuzumab sensitivity in 
gastric cancer.
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Trastuzumab · Cetuximab · Ligand
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Abstract 
Purpose Gastric cancer remains a major health concern, 
and improvement of the therapeutic options is crucial. 
Treatment with targeted therapeutics such as the EGFR-
targeting antibody cetuximab or the HER2-targeting anti-
body trastuzumab is either ineffective or moderately effec-
tive in this disease, respectively. In this study, we analysed 
the involvement of the HER receptor ligands amphiregulin 
(AREG), epidermal growth factor (EGF), heparin-bind-
ing epidermal growth factor (HB-EGF) and transforming 
growth factor alpha (TGFα) in the responsiveness of gastric 
cancer cell lines to cetuximab and trastuzumab.
Methods A panel of 11 gastric cancer cell lines was char-
acterized for cetuximab and trastuzumab sensitivity, ligand 
secretion and expression and activation of the HER recep-
tors using WST-1 cell proliferation assays, ELISAs and 
Western blot analyses. We further investigated the effects 
of an exogenous ligand application on the cetuximab and 
trastuzumab sensitivity.
Results We found no correlation between TGFα secre-
tion and the sensitivity to cetuximab or trastuzumab. For 
AREG, we confirmed previous results indicating that this 
ligand is a positive predictor of cetuximab sensitivity. 
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rpm  Rounds per minute
RTK  Receptor tyrosine kinase
SCCHN  Squamous cell carcinoma of the head and neck
SD  Standard deviation
TGFα  Transforming growth factor alpha
Introduction
According to estimates, in 2012, 951,000 new gastric can-
cer cases were diagnosed worldwide and 723,000 patients 
died of their disease. Hence, gastric cancer was ranked as 
the fifth most common cancer in the world (Ferlay et al. 
2015).
Although important progress in gastric cancer preven-
tion has been achieved in recent years, therapeutic options, 
especially for advanced disease, are still limited. The stand-
ard treatment for unresectable or metastatic disease is still 
palliative chemotherapy, generally based on a platinum/
fluoropyrimidine regimen (Okines et al. 2010). Following 
the development of targeted cancer therapeutics, the HER 
receptors have been favoured as putative molecular targets 
in gastric tumours. Due to their frequent overexpression in 
tumours, research efforts especially concentrated on EGFR 
(HER1) and HER2 [for review: (Hinoda et al. 2004)]. 
Finally, the approval of the monoclonal HER2-targeted 
antibody trastuzumab for the treatment of advanced or 
metastatic gastric cancer showed the potential of targeted 
therapies in this illness (Bang et al. 2010).
Additionally, a phase IIa trial investigating the efficacy 
of the HER2-targeted monoclonal antibody pertuzumab in 
combination with trastuzumab, capecitabine and cisplatin 
in patients with HER2-positive advanced gastric cancer or 
cancer of the gastro-oesophageal junction was the basis for 
an ongoing phase III study of first-line pertuzumab, tras-
tuzumab and chemotherapy in HER2-positive metastatic 
gastric and gastro-oesophageal junction cancer (JACOB, 
NCT01774786) (Kang et al. 2014).
In contrast, the EGFR/HER2 small-molecule inhibitor 
lapatinib showed only limited efficacy in treating advanced 
gastric cancer (Hecht et al. 2016; Lorenzen et al. 2015; 
Satoh et al. 2014). EGFR-targeted therapeutics have been 
ineffective so far: the addition of the EGFR-targeted anti-
body cetuximab to chemotherapy failed to show any sig-
nificant benefit in the phase III EXPAND trial (Lordick 
et al. 2013), the addition of the anti-EGFR antibody pani-
tumumab to chemotherapy did not improve overall survival 
of patients in the phase III REAL3 trial (Waddell et al. 
2013), and in the SWOG 0127 trial, the small-molecule 
inhibitor erlotinib did not improve the outcome of patients 
with metastatic or unresectable gastric cancer (Dragovich 
et al. 2006).
The rationale for these findings is unclear and has yet 
to be clarified. Several different resistance mechanisms 
against EGFR- and HER2-targeted therapies have been 
discovered in recent years. In colorectal cancer, activat-
ing mutations in the KRAS gene were shown to be asso-
ciated with therapeutic failure of cetuximab-containing 
regimens (Karapetis et al. 2008; Lievre et al. 2006). 
Recently, results were published suggesting that activat-
ing PIK3CA mutations are associated with reduced effi-
cacy of trastuzumab- and lapatinib-based therapies in 
breast cancer patients (Majewski et al. 2015). Berns and 
co-authors associated PIK3CA mutations and low PTEN 
expression with a reduced progression-free survival of 
trastuzumab-treated breast cancer patients (Berns et al. 
2007). Besides, several other resistance mechanisms 
against HER2-targeted therapeutics have been proposed, 
including enhanced expression and activation of HER3 
and functional crosstalk with the receptor tyrosine kinase 
MET [for review: (Shimoyama 2014)]. In addition to 
other receptor tyrosine kinases and the downstream sig-
nalling pathways, the ligand system of the HER receptors 
has been spotlighted as a potential source for resistance 
mechanisms against HER receptor-targeting therapeutics. 
Among the family of HER receptor ligands, amphiregu-
lin (AREG) and epiregulin in particular have been studied 
for their involvement in the responsiveness of tumours to 
cetuximab-containing regimens (Baker et al. 2011; Cush-
man et al. 2015; Jacobs et al. 2009; Jonker et al. 2014; 
Khambata-Ford et al. 2007; Pentheroudakis et al. 2013; 
Takahashi et al. 2014; Yoshida et al. 2013). Although 
HER2 does not possess a functional ligand-binding 
domain, some findings suggest that the HER receptor 
ligand system is involved in trastuzumab resistance as 
well (Kim et al. 2015; Ritter et al. 2007; Valabrega et al. 
2005; Yotsumoto et al. 2010). These studies focused 
mainly on cetuximab treatment of colorectal cancer and 
tumours of the head and neck as well as trastuzumab 
treatment in breast cancer. To expand these data, the aim 
of our study was to investigate the role of the HER recep-
tor ligand system in the responsiveness of gastric cancer 
cells to cetuximab and trastuzumab, with special focus 
on AREG, transforming growth factor alpha (TGFα) and 
heparin-binding epidermal growth factor (HB-EGF).
Materials and methods
Cell lines and cell culture conditions
The cell lines AGS, Hs746T, KATOIII, LMSU, MKN1, 
MKN28 and MKN45 were obtained and cultured as 
described previously (Heindl et al. 2012; Kneissl et al. 
575J Cancer Res Clin Oncol (2017) 143:573–600 
1 3
2012). The cell lines GSU, H111TC, HGC-27 and MKN7 
were provided by the Cell Bank RIKEN BioResource 
Center (Tsukuba, Japan), and the identity of the cell 
lines was guaranteed by the provider. GSU, H111TC and 
MKN7 cells were grown in RPMI-1640 medium (Invitro-
gen/Gibco, Darmstadt, Germany), and HGC-27 cells were 
cultured in Eagle’s minimum essential medium (MEM, 
Sigma-Aldrich Chemie GmbH, Taufkirchen, Germany). 
Both media were supplemented with 10% foetal bovine 
serum Sera Plus (PAN Biotech, Aidenbach, Germany) 
and penicillin–streptomycin (PAA Laboratories, Pasching, 
Austria; 100 international units (IU)/ml, 100 μg/ml); in 
addition, RPMI-1640 was supplemented with 2 mM l-glu-
tamine (Invitrogen/Gibco). General cultivation conditions 
and routine mycoplasma testing as well as cell line valida-
tion were performed as described previously (Heindl et al. 
2012; Kneissl et al. 2012).
Antibodies and reagents
For Western blot analysis, the following antibodies were 
used: anti-EGFR (Cell Signaling, Leiden, NL, #2232), anti-
pEGFR (Y1068) (Invitrogen, #44788G), anti-HER2 (Cell 
Signaling, #2165), anti-pHER2 (Y1248) (Cell Signaling, 
#2247), anti-HER3 (Cell Signaling, #4754), anti-pHER3 
(Y1222) (Cell Signaling, #4784), anti-HER4 (Cell Signal-
ing, #4795), anti-pHER4 (Y1284) (Cell Signaling, #4757), 
anti-TACE (Cell Signaling, #6978), anti-β-actin (Sigma-
Aldrich, #A1978), anti-α-tubulin (Sigma-Aldrich, #T9026), 
anti-rabbit IgG (Cell Signaling, #7074) and anti-mouse IgG 
(GE Healthcare, Munich, Germany, #NA931).
The following monoclonal therapeutic antibodies were 
used: cetuximab (Erbitux™, Merck Serono, Darmstadt, 
Germany), trastuzumab (Herceptin™, Roche, Penzberg, 
Germany) and isotype control (Southern Biotech, Bir-
mingham, USA, #0151K-14). The corresponding sol-
vent controls were as follows: solvent control isotype: 
1 × PBS; solvent control trastuzumab: 3.36 mg l-histi-
dine HCl, 2.16 mg l-histidine, 136.2 mg trehalose dihy-




The solvent control for cetuximab was described previ-
ously (Heindl et al. 2012).
Recombinant ligands were obtained as follows: human 
AREG (R&D systems, Minneapolis, USA, #262-AR-100), 
human HB-EGF (Pelobiotech, Planegg, Germany; #PB-
Z3051) and human EGF (Sigma-Aldrich, #E9644).
Chemotherapeutics were obtained as follows: 5-fluoro-
uracil (Sigma-Aldrich, #F6627), cisplatin (Sigma-Aldrich, 
#P4394).
WST‑1 cell proliferation assay
To assess the effects of the treatments on cell prolifera-
tion, the WST-1 cell proliferation assay was used accord-
ing to the manufacturer’s instructions (Roche Diagnos-
tics, Mannheim, Germany; #11644807001). All samples 
were analysed in triplicate. Cells were seeded at densities 
between 0.5 × 103 and 5 × 103 cells per well in 80 µl cul-
ture medium and allowed to settle for 24 h. The following 
day, cetuximab and/or trastuzumab and/or recombinant 
human AREG, EGF or HB-EGF and/or chemotherapeutics 
were added to a final volume of 100 µl per well. The iso-
type control was added to a final concentration of 100 µg/
ml for cetuximab and 40 µg/ml for trastuzumab. Due to 
the high volume needed, we investigated the effect of the 
isotype solvent as well. The applied volume for the cetuxi-
mab solvent corresponded to 100 µg/ml cetuximab, and the 
trastuzumab solvent corresponded to 40 µg/ml trastuzumab. 
Assays using cetuximab were incubated for 48 h, and 
assays with trastuzumab were incubated for 72 h. Experi-
ments with concomitant treatment of cetuximab and tras-
tuzumab were incubated for 72 h as well. After this incu-
bation period, pre-warmed WST-1 reagent was added. The 
absorbance of the samples was measured after an incuba-
tion period between 30 min and 2 h, depending on the cell 
line. An Asys Expert Plus microplate reader was used for 
measurements (Biochrom, Berlin, Germany).
Extraction of genomic DNA
For extraction of genomic DNA from GSU and H111TC 
cells, the DNeasy kit was used according to manufacturer’s 
instructions (Qiagen, Hilden, Germany; #69504). The DNA 
concentration was measured using the QuBit 2.0 DNA high 
sensitivity kit (Thermo Fisher Scientific, Waltham, USA, 
#Q32854). Furthermore, DNA sequencing grade quality 
was determined by a qPCR assay (RNAse P assay, Thermo 
Fisher Scientific, Waltham, USA, #4316831) as described 
previously (Endris et al. 2013).
Library preparation and semiconductor sequencing
For library preparation, the multiplex PCR-based Ion Torrent 
AmpliSeq™ technology (Thermo Fisher Scientific, Waltham, 
USA), together with the Cancer Hotspot Panel (CHPv2; 
Thermo Fisher Scientific, #4475346), was used as described 
previously (Endris et al. 2013; Stenzinger et al. 2014).
Amplicon library preparation was performed with the 
Ion AmpliSeq Library Kit v2.0 (Thermo Fisher Scien-
tific, #4480442). For mutation analysis, the CHPv2 panel, 
which consists of one primer pool yielding 207 ampli-
cons covering hot spot regions of 50 known cancer-related 
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genes, was employed. For amplification, approximately 
10 ng of DNA, as determined by qPCR assay, was used. 
Briefly, the DNA was mixed with the primer pool and the 
AmpliSeq HiFi Master Mix in a 20-µl reaction volume and 
transferred to a PCR cycler (Biometra, Göttingen, Ger-
many). After the end of the PCR, amplicons were partially 
digested using FuPa reagent, followed by the ligation of 
barcoded sequencing adapters (Ion Xpress Barcode Adapt-
ers, Thermo Fisher Scientific, #4474517). The final library 
was purified using AMPure XP magnetic beads (Beckman 
Coulter, Krefeld, Germany, # A63880) and quantified using 
qPCR (Ion Library Quantitation Kit, Thermo Fisher Scien-
tific, #4468802) on a StepOnePlus qPCR machine (Thermo 
Fisher Scientific, Waltham, USA). The individual libraries 
were diluted to a final concentration of 100 pM. All librar-
ies were pooled and processed for library amplification 
on Ion Spheres using Ion PGM™ Template OT2 200 Kit 
(Thermo Fisher Scientific, #4480974). Unenriched libraries 
were quality controlled using an Ion Sphere quality control 
measurement on a QuBit instrument. After library enrich-
ment (Ion OneTouch ES, Thermo Fisher Scientific), the 
library was processed for sequencing using the Ion PGM™ 
Sequencing 200 Kit v2 chemistry (Thermo Fisher Scien-
tific, #4482006) and the barcoded libraries were loaded 
onto a 318v2 chip.
Data analysis
Raw sequencing data were processed using the imple-
mented Torrent Suite software (version 4.4.3) and aligned 
with the human genome (version hg19) using the TMAP 
algorithm. For DNA mutation analysis, the aligned reads 
were processed using the built-in Variant Caller plugin (ver-
sion 4.4.3). Variant annotation was performed using a cus-
tom-build variant annotation pipeline in the CLC Genomics 
Workbench (version 8.0.2). For visualization of sequencing 
and fusion reads, the Integrative Genomic Browser (IGV, 
http://www.broadinstitute.org/igv/) was used. We used 
the COSMIC (catalogue of somatic mutations in cancer) 
database (Forbes et al. 2015; Sherry et al. 2001) to iden-
tify already known somatic mutations and mutation types, 
respectively.
Prediction of copy number alterations
Copy number variations (CNVs; amplifications and dele-
tions) were identified using the coverage data summary for 
each sample and each amplicon generated by the Torrent 
Suite software. Detection of CNVs was performed accord-
ing to Endris et al. (2013). In brief, gene amplifications 
and/or deletions were determined by a simple algorithm 
using the number of reads of each individual amplicon 
in the sequenced sample: (i) the number of reads of each 
individual pool amplicon was divided by the total num-
ber of sequencing reads of the respective sample = (reads 
amplicon x/total reads) = normalized amplicon read depth 
value (NARD); (ii) the NARD was multiplied by the 
total number of amplicons (e.g. lung cancer panel = 140 
amplicons; NARD (reads amplicon x/total reads) × 140); 
(iii) the median normalized amplicon read depth 
(MNARD) was determined for all samples = median 
(NARDSample1:NARDSampleX), reflecting the typical 
amplification efficiency of each individual amplicon in the 
pool; and iv) the standard deviation (SD) was determined 
from the median value. Amplifications are considered true 
if the NARDs of all amplicons covering a gene differ by 
>2 SD from the median value. However, deletions are con-
sidered true if the SD of all amplicons covering a gene is 
<0.5.
Array‑comparative genomic hybridization
Array-comparative genomic hybridization (aCGH) was 
performed as previously described (Juskevicius et al. 
2016; Ruiz et al. 2011), with minor modifications. In brief, 
500 ng of sample DNA (cell line DNA of GSU or H111TC) 
and equal amounts of female reference genomic DNA 
(Promega, Madison, WI, USA) were digested with DNa-
seI to a size range of 200–500 bp. Subsequent labelling 
of sample and reference DNA with Cy3-dUTP and Cy5-
dUTP, respectively, was performed with the BioPrime® 
Array CGH Genomic Labeling System (Invitrogen, Carls-
bad, CA, USA). The success of labelling was assessed by 
quantifying the specific activities of the incorporated dyes 
with a Nanodrop (Thermo Fischer Scientific, Waltham, 
MA, USA). Reference and sample DNA were mixed and 
hybridized to 180 k CGH arrays (Agilent Technologies, 
Santa Clara, CA, USA) for 24 h in a rotating oven at 67 °C. 
Microarray slides were scanned with the Agilent 2565C 
DNA scanner, and images were analysed with Agilent’s 
Feature Extraction using default settings. Feature extracted 
array CGH data were evaluated using Agilent’s CytoG-
enomics software v3.0.1.1. Aberrations were called with 
the aberration detection algorithm ADM2 set to a thresh-
old of 12.0, with fuzzy zero and GC-content (window size: 
2 kb) correction. A minimum of three probes were neces-
sary to call an aberration.
ELISA
For detection of human AREG, HB-EGF and TGFα, Duo-
Set ELISAs were used (R&D systems, Minneapolis, USA; 
#DY262, DY259, DY239) according to the manufacturer’s 
instruction. All samples were analysed in duplicates.
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To determine the levels of secreted ligand (AREG, HB-
EGF, TGFα), 1 × 106 cells were seeded into 10 ml medium 
and incubated for 24 h. Next, conditioned cell culture 
medium was harvested and centrifuged at maximum speed 
(4 °C) for 10 min to remove cell debris. Aliquots were 
stored at −80 °C.
For analysis of the effect of trastuzumab treatment 
in combination with an exogenous ligand application 
on ligand secretion, 2 × 105 cells (MKN45, GSU) were 
seeded into 2 ml medium. Cells were allowed to settle 
overnight. The following day, the cells were treated with 
medium containing 10 µg/ml trastuzumab and/or 15 ng/
ml AREG or 0.1 ng/ml EGF or 0.4 ng/ml HB-EGF for 6 h. 
The conditioned medium was harvested and stored as men-
tioned above.
The effect of extensive trastuzumab and cetuximab 
treatment was analysed by seeding 2 × 105 cells into 
6 ml medium. After 24 h, 10 µg/ml cetuximab or trastu-
zumab was added. The cells were incubated for 8 days 
with medium changes every 3–4 days. Then, the cells 
were trypsinized and 2 × 105 cells were seeded into 2 ml 
medium containing 10 µg/ml cetuximab or trastuzumab. 
Conditioned medium was harvested after 24 h as men-
tioned above.
Western blot
For analysis of the effect of trastuzumab treatment in 
combination with an exogenous ligand on protein lev-
els, 2 × 105 cells (MKN45, GSU) were seeded into 2 ml 
medium. Cells were allowed to settle overnight. The fol-
lowing day, the cells were treated with medium containing 
10 µg/ml trastuzumab and/or 15 ng/ml AREG, 0.1 ng/ml 
EGF or 0.4 ng/ml HB-EGF for 6 h. The effect of exten-
sive trastuzumab and cetuximab treatment was analysed 
by seeding 2 × 105 cells into 6 ml medium. After 24 h, 
10 µg/ml cetuximab or trastuzumab was added. The cells 
were incubated for 8 days with medium changes every 
3–4 days. Cell lysates were prepared as described previ-
ously (Bremm et al. 2008). Western blot analysis was per-
formed using a standard protocol described previously. 
The antibodies were used in the following dilutions: anti-
EGFR, anti-HER2, anti-pHER2, anti-HER3, anti-pHER3, 
anti-HER4 and anti-pHER4: 1:1000 in 5% BSA-TBS-T 
(w/v); anti-pEGFR: 1:2000 in 5% milk-TBS-T (w/v); anti-
TACE: 1:3000 in 5% milk-TBS-T (w/v); anti-β-actin, anti-
α-tubulin, anti-mouse IgG: 1:10,000 in 5% milk-TBS-T 
(w/v); anti-rabbit IgG: 1:2000 in TBS-T. Signal detection 
was performed using an enhanced chemiluminescence 
reaction. The signals were quantified by densitometric 
measurement via ImageJ software 1.42q (National Institute 
of Health, MD, USA).
Literature search
A PubMed search was performed for relevant gastric can-
cer-based literature about the HER receptor ligands AREG, 
EGF, HB-EGF and TGFα (date: 6 May 2015). The search 
was performed using the following terms: amphiregulin 
gastric cancer, EGF gastric cancer, HB-EGF gastric cancer, 
TGFα gastric cancer.
Inclusion criteria were as follows: (1) published as an 
original article, (2) published in the English language, (3) 
full-text access, (4) examined ligand mRNA levels, ligand 
protein levels or pro-ligand protein levels in (5) tissue, 
serum, gastric juice and other body fluids of gastric cancer 
patients. Studies dealing only with tumours of the gastroe-
sophageal junction (GEJ) were excluded as well as studies 
based on less than 10 patients and studies with an unclear 
number of tumour samples. Furthermore, studies concern-
ing gene polymorphisms in ligand genes and their associa-
tion with gastric cancer risk were excluded. Additionally, 
all studies regarding only co-expression of HER ligands 
in combination with other proteins were not included. The 
studies were screened for relevant information regarding 
the expression rates of the ligands and their correlation to 
clinicopathologic features.
Statistical analysis
All analyses presented herein were performed in at 
least three independent experiments. Statistical analy-
ses were calculated using IBM SPSS Statistics 22 (IBM, 
Armonk, NY, USA). The results are shown as the mean 
value ± standard deviation (SD). For comparing pairs of 
different treatment conditions, the two-sided Welch t test 
was used. When values were compared to a reference value 
(=100%), we used the one-sample t test. p values ≤0.05 
are indicated by * and ≤0.01 by **. The authors will pro-
vide all statistical analyses on request.
Results
Trastuzumab and cetuximab sensitivity of gastric 
cancer cell lines
In this study, a panel of 11 gastric cancer cell lines was used. 
In addition to the data we published recently (Heindl et al. 
2012; Kneissl et al. 2012), we identified the cell lines GSU, 
H111TC and MKN7 as cetuximab sensitive (Table 1, Online 
Resource 1). Following treatment with 10 µg/ml cetuxi-
mab, GSU cells displayed a decrease in cell proliferation to 
68.10% in comparison with the untreated control (p = 0.04). 
H111TC cells were less sensitive with growth rates of 82.30% 
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after treatment with 10 µg/ml cetuximab (p = 0.002) and a 
maximum inhibition to 80.16% after application of 200 µg/
ml (p < 0.001). MKN7 cells showed only a minor sensitiv-
ity with a maximum decrease of cell proliferation to 83.63% 
following treatment with 100 µg/ml cetuximab (p = 0.001). 
HGC-27 cells were completely resistant to cetuximab.
Additionally, we investigated the trastuzumab sensitiv-
ity of the cell lines via cell proliferation assay (Fig. 1). We 
identified two cell lines as trastuzumab sensitive: GSU and 
H111TC. Both displayed a significant decrease in cell prolif-
eration after application of the therapeutic. For GSU, 0.1 µg/
ml was already sufficient to inhibit the proliferation rate to 
80.10% (p = 0.009), while 40 µg/ml caused an inhibition 
to 72.98% (p = 0.002). H111TC displayed a less sensitive 
phenotype with a maximum inhibition to 80.03 and 80.31% 
after application of 20 µg/ml and 40 µg/ml trastuzumab 
(p = 0.024; p = 0.02), respectively. For the other cell lines, 
no significant inhibition of cell proliferation was observed.
Genetic alterations in gastric cancer cell lines
Among the numerous genetic alterations which have been 
connected to resistance to cetuximab, activating mutations 
in the KRAS gene are especially important in colorectal 
cancer regimens (Karapetis et al. 2008; Lievre et al. 2006). 
Regarding trastuzumab therapy, activating mutations in the 
PIK3CA gene have been described to be associated with 
a poorer therapy outcome in breast cancer patients (Berns 
et al. 2007; Majewski et al. 2015). Additionally, the exist-
ence of HER2 amplifications and the resulting consecu-
tive overexpression of the protein are crucial factors in the 
response predictions for trastuzumab-based regimens in 
patients with gastric cancer (Okines et al. 2010). There-
fore, we collected information about these three genetic 
loci in our panel of gastric cancer cell lines. We were able 
to extract some data from the literature and completed the 
missing data for the majority of the cell lines with our own 
analyses (Table 1).
Interestingly, we found that the cetuximab-sensitive cell 
line GSU harbours an activating KRAS mutation in exon 
2 (G12D), and MKN1 cells, which are cetuximab sensi-
tive, were described as KRAS amplified (Mita et al. 2009). 
However, activating PIK3CA mutations have only been 
described for trastuzumab-insensitive cell lines (MKN1, 
HGC-27, AGS, MKN45) (Mita et al. 2009; Zhou et al. 
2011), while we found both sensitive cell lines, GSU and 
Table 1  Molecular and physiological characteristics of gastric cancer cell lines used in this study
Bold = results obtained in this study; 1 online resource 1; 2 online resource 7; 3 exon 2–4; 4 codon 12/13; 5 exon 1/2; 6 exon 2; 7 exons 9, 20; 8 
screening for E542K, E545D, E545K, H1047R, H1047L; 9 online resource 2; 10 online resource 3, 4; ND not described
Cell line Cetuximab sensitivity AREG secretion KRAS mutation PIK3CA mutation HER2 amplification
AGS − (Heindl et al. 2012) − (Kneissl et al. 2012) G12D (Kim et al. 2003) E545A7 (Mita et al. 
2009)
Not amplified (Wainberg 
et al. 2010)
GSU +++1 +++2 G12D3 WT7 No suspected copy num‑
ber variations9
Not amplified10
H111TC ++1 +++2 WT3 WT7 Suspected copy number 
variations9
Amplification10
HGC-27 −1 −2 WT5 (Kubo et al. 2009) E542K7 (Zhou et al. 
2011)
Not amplified (Nam et al. 
2012)
Hs746T − + (Kneissl et al. 2012) WT6 (Kneissl et al. 
2012)
WT7 (Kneissl et al. 
2012)
Not amplified (Zang et al. 
2011)
KATOIII − (Heindl et al. 2012) ++ WT5 (Kubo et al. 2009) WT8 (Li et al. 2013) Not amplified (Wainberg 
et al. 2010)
LMSU − − (Kneissl et al. 2012) WT6 (Kneissl et al. 
2012)
WT7 (Kneissl et al. 
2012)
ND
MKN1 ++ ++ (Kneissl et al. 2012) Amp (Mita et al. 2009) E545K7 (Mita et al. 
2009)
Not amplified (Wainberg 
et al. 2010)
MKN7 +1 ++2 WT4 (Mita et al. 2009) ND Amplification (Fukushige 
et al. 1986)
MKN28 ++ (Heindl et al. 2012) ++ (Kneissl et al. 2012) WT4 (Mita et al. 2009) ND Not amplified (Zang et al. 
2011)
No high-level amplifica-
tion (Takada et al. 2005)
MKN45 − (Heindl et al. 2012) − (Kneissl et al. 2012) WT5,4 (Kubo et al. 2009; 
Mita et al. 2009)
H1047R7 (Zhou et al. 
2011)
Not amplified (Nam et al. 
2012)
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H111TC, to be wild type. Regarding the HER2-amplifi-
cation status, the picture was less consistent as we found 
a suspected HER2 amplification only for the cell line 
H111TC by next-generation sequencing (Online Resource 
2) which was confirmed by array-comparative genomic 
hybridization (ERBB2/CEP7 ratio > 2.0) (Online Resource 
3, 4).
Enhanced inhibition of gastric cancer cell growth 
by trastuzumab in combination with chemotherapeutics 
but not with cetuximab
In our cells, trastuzumab monotreatment showed only a 
moderate effect on cell proliferation. Therefore, we decided 
to investigate the effect of a concomitant application of 
cetuximab or chemotherapeutics (5-fluorouracil [5-FU] and 
cisplatin) to trastuzumab.
Although GSU cells are sensitive to trastuzumab as well 
as to cetuximab, a combination of both monoclonal anti-
bodies failed to show any enhancing effect in comparison 
with the monotreatment (Fig. 2a). However, the addition 
of 5-FU and cisplatin to trastuzumab led to significantly 
stronger growth inhibition in GSU cells than trastuzumab 
or chemotherapy alone (Fig. 2b). This effect was not 
observed in the trastuzumab-insensitive cell line MKN45, 
although this cell line reacted to the monotreatment with 
chemotherapeutics with a significant growth inhibition 
(p = 0.02).
Fig. 1  Effect of trastuzumab treatment on the cell proliferation of 
gastric cancer cell lines. The gastric cell lines AGS, GSU, H111TC, 
HGC-27, Hs746T, KATOIII, LMSU, MKN1, MKN7, MKN28 and 
MKN45 were treated for 72 h with the indicated amounts of trastu-
zumab (0/0.1/1/10/20/40 µg/ml), a solvent control (Sol), an isotype 
control (ISO) or isotype solvent control (ISO-Sol). Afterwards, the 
metabolic activity of the cell lines was determined via WST-1 cell 
proliferation assay. Only GSU and H111TC cells were trastuzumab 
sensitive (dark grey diagrams). The mean value of at least three 
independent experiments is shown. p values at significance levels of 
≤0.050 and ≤0.010 are indicated by (*) and (**), respectively
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Effects of extended trastuzumab and cetuximab 
treatment on the expression and activation of HER 
receptors
To determine the effect of an extended application of tras-
tuzumab and cetuximab on the expression and activation 
of the HER receptors, we treated all cell lines with the 
therapeutics for 8 days and measured the expression of 
EGFR, pEGFR, HER2, pHER2, HER3, pHER3, HER4 
and pHER4 (Figs. 3, 4, Online Resource 5, 6). The basal 
expression rate of EGFR, pEGFR, HER2, pHER2, HER3 
and pHER3 varied highly between the cell lines. The high-
est EGFR levels were expressed by MKN1 cells; AGS, 
GSU, Hs746T, KATOIII, MKN7 and MKN28 cells dis-
played medium expression levels, and in MKN45, LMSU, 
H111TC and HGC-27 cells, EGFR was hardly detect-
able. In contrast to these findings, pEGFR was expressed 
at the highest levels by KATOIII and MKN45 cells, a 
medium expression rate was detected in GSU, H111TC, 
Hs746T and MKN7 cells, and pEGFR was barely detect-
able in AGS, HGC-27, LMSU, MKN1 and MKN28 cells. 
For AGS, Hs746T, KATOIII, LMSU, MKN1, MKN28 and 
MKN45, these findings support our recently published 
results (Heindl et al. 2012; Kneissl et al. 2012). Regard-
ing HER2, the highest levels were expressed by MKN7 
cells, medium levels were expressed by GSU, H111TC, 
HGC-27, KATOIII, LMSU and MKN1 cells, and HER2 
expression was hardly detectable in AGS, Hs746T, MKN28 
and MKN45 cells. We were able to detect medium levels 
of pHER2 in GSU, H111TC, Hs746T KATOIII, MKN7 
and MKN45 cells, while in all other cell lines, the pro-
tein was hardly detectable. All cell lines, with the excep-
tion of LMSU (no expression) and GSU (high expression), 
expressed HER3 at median levels; however, we were only 
able to regularly detect pHER3 above the background level 
in KATOIII cells. pHER4 could not be detected in any cell 
line, and only HGC-27 cells displayed a medium expres-
sion of HER4. Regarding the effect of 8 days of cetuximab 
treatment on the expression levels, we found no obvious 
patterns for EGFR, pEGFR, HER3 and pHER3. However, 
densitometric measurement revealed an increase in the 
expression of HER2 after treatment for 8 of 11 cell lines 
(significant for H111TC and MKN7 cells; p = 0.041; 
p = 0.029). pHER2 expression was enhanced in 10 out of 
11 cell lines, but this effect was only significant for MKN7 
(p = 0.028). Regarding the effect of 8 days of trastuzumab 
treatment, relevant patterns were only observed for HER2. 
H111TC, HGC-27, MKN1 and MKN28 all displayed a 
significant decrease in HER2 expression after trastuzumab 
treatment (p = 0.003; 0.01; 0.038; 0.015, respectively). 
Furthermore, pHER3 levels significantly decreased in 
Hs746T and MKN7 cells. Additionally, we investigated 
the effect of the trastuzumab and cetuximab treatment on 
the expression of the protein TACE which is responsible 
for the cleavage of the membrane-bound ligand precursors 
into the soluble ligand [for review: (Mochizuki and Okada 
2007; Sternlicht and Sunnarborg 2008)]. We detected only 
for GSU cells after trastuzumab treatment a significant 
decrease indicating only a minor influence of cetuximab or 
trastuzumab treatment on TACE expression in gastric can-
cer cell lines.
HER receptor ligand level in gastric cancer cell lines
We analysed the level of HB-EGF and TGFα in our panel 
of gastric cancer cell lines. For most cell lines, AREG 
secretion had already been determined in a previous study 
(Table 1; Kneissl et al. 2012). In addition, we found that 
GSU, H111TC and MKN7 cells secrete high amounts of 
AREG to the medium, while the AREG secretion of HGC-
27 was barely detectable (Table 1, Online Resource 7).
TGFα levels in the conditioned medium of the cell 
cultures were analysed, and a broad range was detected 
(Fig. 5a). TGFα was hardly detectable with values below 
5 pg/ml in H111TC, HGC-27, LMSU and MKN45 cells. 
Fig. 2  Effect of concomitant treatment of gastric cancer cells with 
trastuzumab and chemotherapeutics or cetuximab on cell prolifera-
tion. GSU and MKN45 cells were treated for 72 h with 10 µg/ml tras-
tuzumab and/or 10 µg/ml cetuximab (a) or chemotherapeutics (25 ng/
ml cisplatin, 2.5 ng/ml 5-FU; b). The metabolic activity of the cells 
was measured using the WST-1 cell proliferation assay. For concomi-
tant trastuzumab and cetuximab treatment, no increased inhibitory 
effect in comparison with the monotreatment was observed. However, 
addition of chemotherapeutics to trastuzumab treatment yielded in 
GSU cells in an enhanced inhibition of cell proliferation, compared 
to trastuzumab or chemotherapeutics alone. The mean value of three 
independent experiments is shown. p values at significance levels of 
≤0.050 and ≤0.010 are indicated by (*) and (**), respectively
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Fig. 3  Effect of treatment with trastuzumab for 8 days on the expres-
sion profile of HER and pHER receptors. All gastric cancer cell lines 
were treated for 8 days with 10 µg/ml trastuzumab; afterwards, the 
expression of EGFR, HER2, HER3, HER4, pEGFR, pHER2, pHER3 
and pHER4 was determined via Western blot analysis. Basal expres-
sion of HER receptors varied highly between the cell lines. No obvi-
ous correlation between basal HER/pHER receptor expression and/
or changes in expression and responsiveness to trastuzumab could be 
observed
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The cell lines AGS, GSU, Hs746T and MKN1 secreted 
medium levels of TGFα in a range between 5 and 10 pg/ml 
in the medium. The highest concentrations were detected 
for KATOIII, MKN7 and MKN28 cells.
HB-EGF was secreted in different concentrations; how-
ever, for the majority of the cell lines, HB-EGF levels were 
below 20 pg/ml. Substantially higher concentrations were 
only secreted by Hs746T, MKN7 and MKN28 cells (Fig. 5b).
Fig. 4  Effect of treatment with cetuximab for 8 days on the expres-
sion profile of HER and pHER receptors. All gastric cancer cell lines 
were treated for 8 days with 10 µg/ml cetuximab; afterwards, the 
expression of EGFR, HER2, HER3, HER4, pEGFR, pHER2, pHER3 
and pHER4 was determined via Western blot analysis. Only minor 
effects of the treatment on HER/pHER receptor profile were detected. 
No obvious correlation between basal HER/pHER receptor expres-
sion and/or changes in expression and responsiveness to cetuximab 
could be observed
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Effects of prolonged trastuzumab and cetuximab 
treatment on HER receptor ligand secretion
To investigate the effect of prolonged trastuzumab treat-
ment on HER receptor ligand secretion, we treated GSU 
cells for 8 days with 10 µg/ml trastuzumab and measured 
the level of AREG, HB-EGF and TGFα in the cell culture 
supernatant. Although we did not observe any significant 
effects on ligand secretion, we found a decreasing trend 
in AREG secretion (p = 0.099). No relevant differences 
regarding the levels of HB-EGF and TGFα were detected 
(Fig. 6a).
In contrast, we observed after 8 days of cetuximab 
treatment an increase in HB-EGF and TGFα levels in 
MKN1 and Hs746T cells, although these effects were 
non-significant. Similar to trastuzumab treatment, applica-
tion of cetuximab caused a significant decrease in AREG 
secretion in the cetuximab-sensitive cell line MKN1 
(p = 0.043), while AREG levels in Hs746T were not 
altered (Fig. 6b).
Effects of exogenous ligand application on trastuzumab 
sensitivity in gastric cancer cell lines
To investigate the effects of exogenous ligands on the tras-
tuzumab sensitivity of gastric cancer cells, we performed 
a concomitant treatment of gastric cancer cell lines with 
AREG, EGF or HB-EGF and trastuzumab. We then meas-
ured the influence of this treatment on the metabolic activ-
ity of the cells via the WST-1 cell proliferation assay.
Ligand application had no effect on the proliferative activ-
ity of the trastuzumab-insensitive cell lines KATOIII and 
MKN45, as no differences between the treatments could be 
observed. In contrast, in the trastuzumab-sensitive cell lines 
GSU and H111TC, a combination of the ligands in addition 
to trastuzumab influenced the trastuzumab sensitivity in dif-
ferent ways. In GSU cells, trastuzumab application (20 µg/
ml) inhibited the proliferative activity to 82.7% compared to 
the untreated control (p = 0.017). EGF and AREG were inef-
fective in rescuing the cells from growth inhibition, as there 
was no significant difference compared with the control. In 
contrast, HB-EGF completely neutralized the inhibitory 
effect of trastuzumab. For H111TC cells, HB-EGF applica-
tion partially rescued the cells from trastuzumab inhibition; 
however, this effect was not significant. Additionally, we 
observed enhanced trastuzumab sensitivity of the cells after 
application of exogenous AREG (Fig. 7; Table 2).
Western blots were performed to investigate the effects 
of parallel treatment with trastuzumab and AREG, EGF, 
HB-EGF on pEGFR and pHER2 levels. For these experi-
ments, a 6-h treatment was chosen. While no effect on 
the trastuzumab-insensitive cell line MKN45 could be 
observed, GSU showed an increase in pEGFR levels after 
the trastuzumab treatment in comparison with the untreated 
control (p = 0.038). Interestingly, concomitant applica-
tion of either ligand suppressed this effect. However, only 
for HB-EGF was this suppression significant (p = 0.05). 
Regarding pHER2, similar, but non-significant patterns 
were observed (Fig. 8, Online Resource 8).
In addition, we measured the levels of the ligands 
AREG, HB-EGF and TGFα in the conditioned medium of 
GSU and MKN45 cells, following treatment for 6 h with 
trastuzumab and/or exogenous ligand (AREG, EGF, HB-
EGF). Levels of HB-EGF and AREG showed no signifi-
cant change with any of the treatments, but application of 
each ligand caused a significantly increased secretion of 
TGFα in GSU cells. Regarding this effect, HB-EGF was 
more effective than EGF, and EGF was more effective than 
AREG. Interestingly, in the trastuzumab-insensitive cell 
line MKN45, a significant decrease of TGFα was observed 
after treatment with AREG/trastuzumab and EGF (Fig. 9).
Fig. 5  Secretion of TGFα and HB-EGF by gastric cancer cell lines. 
Cells were incubated for 24 h before the amount of secreted TGFα 
(a) or HB-EGF (b) was measured in the conditioned medium by 
ELISA. The highest concentrations of TGFα were detected for 
KATOIII, MKN7 and MKN28 cells. For all other cell lines, TGFα 
levels were below 10 pg/ml. The highest concentrations of HB-EGF 
were detected for Hs746T, MKN7 and MKN28 cells. For all other 
cell lines, HB-EGF levels were below 20 pg/ml. The mean value of 
three independent experiments is shown. p values at significance lev-
els of ≤0.050 and ≤0.010 are indicated by (*) and (**), respectively
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Effects of exogenous ligand application on cetuximab 
sensitivity in gastric cancer cell lines
We investigated the effects of different concentrations of 
AREG, EGF and HB-EGF on the cetuximab sensitivity 
of the sensitive cell line MKN1 and the resistant cell line 
Hs746T. We found both, HB-EGF and EGF, but not AREG, 
to be effective in rescuing MKN1 from cetuximab inhibi-
tion. Surprisingly, we detected a minor inhibition in the 
cetuximab-resistant cell line Hs746T by cetuximab applica-
tion; however, exogenous ligand application had no addi-
tional effect (Online Resource 9).
Prognostic relevance of HER receptor ligands in gastric 
cancer as described in the literature
To investigate the relevance of HER receptor ligands in 
gastric tumours, a literature research was performed. As 
shown in Table 3, the expression of AREG, EGF, HB-EGF 
and TGFα in gastric tumours and body fluids of gastric 
cancer patients has been analysed in multiple studies. The 
majority of the articles investigated the expression of EGF 
and TGFα.
EGF protein expression was found in up to 88% of the 
gastric tumour samples, with most studies reporting EGF 
positivity in 29–58% of the cases (Aoyagi et al. 2001; 
Borlinghaus et al. 1993; Docea et al. 2013; Hirayama et al. 
1992; Livingstone et al. 1995; Oda et al. 1990; Onda et al. 
1990; Pryczynicz et al. 2009; Sugiyama et al. 1989; Tahara 
et al. 1986; Yasui et al. 1988; Yoshiyuki et al. 1990). EGF 
was detected in the serum, plasma, urine and gastric juice of 
patients with gastric cancer, while analysis of the malignant 
ascites revealed only very low EGF levels (Chuang et al. 
1994; Dias et al. 2011; Dragovich et al. 2006; Han et al. 
2009; Park do et al. 2014; Yasumoto et al. 2011; Zhang 
et al. 2014). Several studies indicated an association with 
advanced disease, metastatic disease and poor prognosis 
(Czyzewska et al. 2009; Hirayama et al. 1992; Onda et al. 
1990; Tahara et al. 1986; Yasui et al. 1988), while in early 
gastric cancers, per trend a smaller percentage of EGF-pos-
itive tumours was reported (Aoyagi et al. 2001; Hirayama 
et al. 1992; Onda et al. 1990; Tahara et al. 1986; Yasui et al. 
1988). Regarding the predictive value of EGF expression 
for EGFR-targeted therapies, the results are completely 
contradictory; in patients treated with cetuximab combined 
with modified FOLFOX6, low EGF levels were associated 
with a higher response rate (Han et al. 2009). In contrast, 
patients with high EGF serum levels treated with cetuxi-
mab, cisplatin and capecitabine displayed a longer overall 
survival (Zhang et al. 2014). In addition, EGF plasma lev-
els were not found to be predictive for therapy response in 
patients treated with erlotinib (Dragovich et al. 2006).
Fig. 6  Effect of treatment with trastuzumab or cetuximab for 
8 + 1 days on the HER receptor ligand secretion. Cells were treated 
for 8 days with trastuzumab (a; GSU cells) or cetuximab (b; MKN1 
and Hs746T cells). Subsequently, the cells were seeded at defined 
densities and incubated for 24 h. Afterwards, the concentrations of 
AREG, HB-EGF and TGFα in the conditioned medium were deter-
mined using an ELISA. By non-significant trend, AREG secretion 
decreased after trastuzumab treatment. Cetuximab treatment sig-
nificantly decreased AREG secretion of MKN1 cells and non-signif-
icantly increased TGFα and HB-EGF secretion in both, MKN1 and 
Hs746T cells. The mean value of three independent experiments is 
shown. p values at significance levels of ≤0.050 and ≤0.010 are indi-
cated by (*) and (**), respectively
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Similarly inconsistent findings concerning EGFR-tar-
geted therapies were reported for TGFα (Dragovich et al. 
2006; Han et al. 2009; Zhang et al. 2014). Expression of 
the TGFα protein was reported in most studies in between 
35 and 74% of gastric tumours (Celikel et al. 2007; Drago-
vich et al. 2006; Espinoza et al. 2004; Konturek et al. 
2001; Livingstone et al. 1995; Muller and Borchard 1992; 
Saeki et al. 1994). Regarding the general prognostic value 
of TGFα, data are quite inconsistent; high TGFα levels in 
the tumour were correlated with lymph node metastasis, 
poor overall survival, advanced TNM stage and tumour 
size in some studies (Aoyagi et al. 2001; Celikel et al. 
2007; Espinoza et al. 2004; Fanelli et al. 2012). On the 
other hand, no correlation with clinicopathologic features 
and prognosis was reported in another study (Muller and 
Borchard 1992). Furthermore, serum TGFα levels showed 
no correlation with clinicopathologic characteristics (Choi 
et al. 1999).
Only a few studies have investigated the expression of 
AREG in gastric cancer. Positive protein staining was 
reported for 34.8% (pro-AREG) and 51% (AREG) of the 
tumours (Saeki et al. 1994; Yoshida et al. 2012). AREG 
mRNA was detected in malignant as well as in non-malig-
nant tissue (Kitadai et al. 1993; Naef et al. 1996; Nielsen 
et al. 2014). However, an increase of AREG mRNA expres-
sion in tumour tissue was reported twice (Kitadai et al. 
1993; Nielsen et al. 2014). One study found no correlation 
between AREG mRNA expression and staging or histologi-
cal tumour types, and another study reported a significantly 
shorter median survival in patients with pro-AREG-positive 
tumours (Kitadai et al. 1993; Yoshida et al. 2012). In addi-
tion, high AREG concentrations were found in the malig-
nant ascites of gastric cancer patients (Yasumoto et al. 
2011). AREG serum levels were not predictive for response 
rate, median time to progression or median overall survival 
(Han et al. 2009).
Fig. 7  Effect of exogenous ligand application on trastuzumab sen-
sitivity in gastric cancer cell lines. GSU, H111TC, KATOIII and 
MKN45 cells were treated for 3 days with trastuzumab alone (0, 1, 
20 µg/ml) and/or different HER receptor ligands (AREG: 15 ng/ml; 
EGF: 0.1 ng/ml; HB-EGF: 0.4 ng/ml). The metabolic activity of the 
cells was measured using the WST-1 cell proliferation assay. In GSU 
cells, HB-EGF but not AREG and EGF was effective in rescuing the 
cells from trastuzumab treatment. In H111TC, a similar but not sig-
nificant trend was observed. No effect of either ligand was detected 
for the trastuzumab-resistant cell lines KATOIII and MKN45. The 
mean value of three independent experiments is shown. For better 
readability only p values referring to the control are shown. For all 
significant p values, please refer to Table 2. p values at significance 
levels of ≤0.050 and ≤0.010 are indicated by (*) and (**), respec-
tively
586 J Cancer Res Clin Oncol (2017) 143:573–600
1 3
Regarding HB-EGF, data are highly consistent and 
indicate an association with advanced disease: levels of 
soluble HB-EGF were found to be elevated in the serum 
of advanced gastric cancer patients (Chung et al. 2015) 
as well as in malignant ascites of gastric cancer patients 
(Yasumoto et al. 2011). Furthermore, increased expression 
of proHB-EGF and of the cytoplasmic domain of HB-EGF 
in advanced tumour stages was reported (Murayama et al. 
2002; Shimura et al. 2012). Interestingly, there is additional 
evidence that HB-EGF might be a resistance factor against 
5-FU- and cisplatin-based chemotherapies (Suganuma 
et al. 2003).
Discussion
The aim of this study was to investigate the involvement of 
several HER receptor ligands in the response of a panel of 
11 gastric cancer cell lines to cetuximab and trastuzumab. 
Seven of these cell lines had been characterized regarding 
their cetuximab sensitivity in studies published previously 
by our group (Heindl et al. 2012; Kneissl et al. 2012). Four 
additional cell lines were investigated in the present study, 
and we found three cell lines, GSU, H111TC and MKN7, 
to be cetuximab-sensitive, while HGC-27 showed a 
cetuximab-resistant phenotype. Interestingly, we identified 
an activating KRAS mutation in GSU cells. Such mutations 
are known resistance factors against cetuximab in colorec-
tal cancer (Karapetis et al. 2008; Lievre et al. 2006). In a 
previous study, we associated the cetuximab resistance of 
the gastric cancer cell line AGS with an activating KRAS 
mutation (Kneissl et al. 2012). However, this new finding 
indicates that such mutations are not necessarily associated 
with cetuximab resistance in gastric cancer.
Only 2 out of 11 cell lines (18.18%) were sensi-
tive to trastuzumab treatment. To our knowledge, these 
two cell lines, GSU and H111TC, have not been previ-
ously described to be trastuzumab sensitive. Mutations in 
the PIK3CA gene were recently associated with reduced 
response of breast cancer patients to trastuzumab and/
or lapatinib neoadjuvant therapy (Majewski et al. 2015). 
In line with these data, we found no such mutation in hot 
spot regions for both sensitive cell lines, while four of the 
insensitive cell lines were described to harbour mutations 
(Mita et al. 2009; Zhou et al. 2011). For most resistant cell 
lines, the trastuzumab sensitivity had been investigated in 
prior studies. Cell lines we identified as resistant had been 
described to be trastuzumab resistant or mildly sensitive in 
other publications (Liu et al. 2015; Tomioka et al. 2012; 
Wainberg et al. 2010). The minor differences between prior 
Table 2  Effect of exogenous 
ligand application on 
trastuzumab sensitivity
All values were compared to the respective non-trastuzumab-treated reference by one-sample t test (*). 
Furthermore, the two-sided Welch t test was used for pairwise comparison of values treated with the same 
trastuzumab concentration and different ligand treatments (**)
Significant p values (refers to Fig. 7)
Cell line X Y p value
GSU Untreated 1 µg/ml trastuzumab 0.023*
Untreated 20 µg/ml trastuzumab 0.017*
AREG AREG/20 µg/ml trastuzumab 0.022*
EGF EGF/1 µg/ml trastuzumab 0.015*
EGF EGF/20 µg/ml trastuzumab 0.009*
HB-EGF/1 µg/ml trastuzumab 1 µg/ml trastuzumab 0.013**
HB-EGF/1 µg/ml trastuzumab AREG/1 µg/ml trastuzumab 0.046**
HB-EGF/1 µg/ml trastuzumab EGF/1 µg/ml trastuzumab 0.021**
HB-EGF/20 µg/ml trastuzumab 20 µg/ml trastuzumab 0.046**
H111TC Untreated 1 µg/ml trastuzumab 0.043*
Untreated 20 µg/ml trastuzumab 0.028*
AREG AREG/1 µg/ml trastuzumab 0.011*
AREG AREG/20 µg/ml trastuzumab 0.014*
EGF EGF/1 µg/ml trastuzumab 0.044*
EGF EGF/20 µg/ml trastuzumab 0.015*
HB-EGF HB-EGF/1 µg/ml trastuzumab 0.004*
HB-EGF HB-EGF/20 µg/ml trastuzumab 0.003*
HB-EGF/1 µg/ml trastuzumab AREG/1 µg/ml trastuzumab 0.044**
MKN45 AREG AREG/1 µg/ml trastuzumab 0.022*
HB-EGF/20 µg/ml trastuzumab AREG/20 µg/ml trastuzumab 0.026**
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studies and our findings are in the expected range regard-
ing results from cell viability assays. In our study, GSU and 
H111TC showed only a moderate sensitivity to the mono-
clonal antibody with a growth inhibition of approximately 
20% compared to the untreated control. However, we were 
able to enhance this effect by concomitant application of 
chemotherapeutics. These findings reflect the situation in 
gastric cancer patients, as trastuzumab has been combined 
with chemotherapy in the pivotal studies and the effect 
that results from addition of trastuzumab is only moderate 
(Bang et al. 2010; Okines et al. 2010).
On a molecular level, GSU cells showed induction of 
pHER2 (Y1248) expression after treatment with trastu-
zumab for 6 h, while no effect was observed for the resist-
ant cell line MKN45. A similar effect was observed after 
8 days of trastuzumab treatment for GSU and H111TC 
cells; however, the effect was not strong enough to per-
sist in the densitometric measurement. These findings are 
in line with results obtained in breast cancer cells, where 
sensitive cell lines showed enhanced expression of pHER2 
(Y1248) upon trastuzumab therapy (Diermeier et al. 2005; 
Dokmanovic et al. 2014). A similar observation was 
Fig. 8  Effect of trastuzumab and concomitant ligand application 
on pEGFR and pHER2 levels in GSU and MKN45 cells. GSU and 
MKN45 cells were treated for 6 h with 10 µg/ml trastuzumab (Tra) 
and 15 ng/ml AREG (A) or 0.1 ng/ml EGF (E) or 0.4 ng/ml HB-EGF 
(H) or 0.75 ng/ml TGFα (T). Subsequently, pEGFR and pHER lev-
els were determined by Western blot analysis. a Shows representative 
experiments; b shows results of densitometric measurements of three 
independent experiments. Treatment with trastuzumab induced the 
levels of both proteins in GSU cells but not in MKN45 cells. Con-
comitant application of the ligand suppressed this effect in GSU cells 
(significant suppression for pEGFR and HB-EGF). p values at sig-
nificance levels of ≤0.050 and ≤0.010 are indicated by (*) and (**), 
respectively. Only relevant p values are shown. A list with all p values 
is shown in Online Source 6
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reported for NCI-N87 gastric carcinoma cells, although 
another publication found no such effect (Leto et al. 2015; 
Yamashita-Kashima et al. 2011).
Changes in the expression profile of the HER recep-
tors were small following treatment with trastuzumab and 
cetuximab for 8 days. However, trastuzumab treatment 
showed more prominent effects, as HER2 levels were sig-
nificantly downregulated in 4 cell lines, and pHER3 levels 
were found to be downregulated in two cell lines. We were 
not able to correlate these alterations to trastuzumab sen-
sitivity or resistance. In contrast, we were surprised by the 
negligible impact of the cetuximab treatment, as we found 
only two significant increases in HER2 levels and one in 
pHER2 levels. On pEGFR level, we detected a complete 
absence of any effect, a finding that corresponded to results 
published recently by our group (Kneissl et al. 2012). It is 
arguable whether the weaker inhibitory effects of cetuxi-
mab on gastric cancer in comparison with trastuzumab are 
based on these differences.
The main focus of this study was the involvement of 
HER receptor ligands in the sensitivity of gastric cancer 
cell lines to trastuzumab and cetuximab. For our analyses, 
we concentrated mainly on AREG, HB-EGF and TGFα, 
as previous results from our group had shown the absence 
of EGF secretion in gastric cancer cell lines (Kneissl et al. 
2012).
Although there is no known ligand binding to HER2, 
several studies have discussed the involvement of the HER 
receptor ligand system in the resistance to HER2-targeted 
therapies. Elevated levels of TGFα in the serum of breast 
cancer patients were associated with a poor response to 
lapatinib/capecitabine (Rhee et al. 2011). Furthermore, 
TGFα expression was found to be induced by trastuzumab 
application in breast cancer patients (Valabrega et al. 
2005). In addition, in patients with metastatic HER2-pos-
itive breast cancer receiving trastuzumab plus taxane, the 
progression-free survival was significantly shortened in 
patients with high serum concentrations of AREG (Kim 
et al. 2015). In cell culture, breast cancer cells with second-
ary resistance to trastuzumab displayed an up-regulation of 
mRNA expression for EGF, TGFα, HB-EGF and heregulin, 
while the expression of AREG mRNA was downregulated 
and the expression of epiregulin and betacellulin mRNA 
was unchanged. Levels of secreted TGFα in the cell cul-
ture medium were found to be increased as well. Further-
more, co-treatment of BT-474 breast carcinoma cells with 
TGFα and trastuzumab neutralized the inhibition of the 
cell growth by trastuzumab (Ritter et al. 2007). Addition-
ally, HB-EGF expression was linked to trastuzumab resist-
ance in breast cancer cells (Yotsumoto et al. 2010). In our 
study, only secretion of TGFα increased in GSU cells after 
6 h of trastuzumab treatment; however, this effect was not 
Fig. 9  Effect of trastuzumab 
and concomitant ligand 
application on AREG, TGFα 
and HB-EGF levels in GSU 
and MKN45 cells. GSU and 
MKN45 cells were treated 
for 6 h with 10 µg/ml tras-
tuzumab (Tra) and the HER 
receptor ligands (Lig) 15 ng/
ml AREG (A) or 0.1 ng/ml 
EGF (E) or 0.4 ng/ml HB-EGF 
(H) or 0.75 ng/ml TGFα (T). 
Subsequently, concentrations of 
secreted AREG, HB-EGF and 
TGFα were determined in the 
conditioned cell culture medium 
using ELISAs. Application of 
each ligand caused a significant 
increase of TGFα secretion in 
GSU cells. For this, HB-EGF 
was more effective than EGF, 
and EGF was more effective 
than AREG. The mean value 
of three independent experi-
ments is shown. p values at 
significance levels of ≤0.050 
and ≤0.010 are indicated by (*) 
and (**), respectively
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significant. After 8 days of trastuzumab application, we 
found a non-significant decrease of AREG secretion, while 
HB-EGF and TGFα were unaltered. The reasons for the 
differences in the findings mentioned above are likely due 
not only to different tumour entities but also to differences 
in the experimental setting, as Ritter et al. used a xenograft-
based approach with a substantially longer period of tras-
tuzumab treatment to isolate cancer cells with secondary 
trastuzumab resistance. We were not able to find any cor-
relation between the levels of secreted TGFα and the sensi-
tivity to trastuzumab. However, regarding HB-EGF, the two 
sensitive cell lines GSU and H111TC showed only minor 
HB-EGF secretion and the three cell lines displaying the 
highest amounts of HB-EGF in the conditioned medium, 
Hs746T, MKN7 and MKN28, were all trastuzumab resist-
ant. Additionally, exogenous HB-EGF application neutral-
ized the growth inhibition by trastuzumab completely in 
GSU cells and partially in H111TC cells. In GSU cells, 
this effect was accompanied by a block of the trastuzumab-
driven induction of pHER2 (Y1248) expression. These 
findings indicate that HB-EGF is effective in neutralizing 
the effects of trastuzumab in gastric cancer cells.
The influence of the HER receptor ligand system on the 
responsiveness of solid tumour to cetuximab has been topic 
of numerous studies published in the last years, although 
only few studies dealt with the situation in gastric cancer.
In colorectal cancer patients, AREG expression in par-
ticular has been repeatedly associated with an enhanced 
responsiveness to cetuximab, especially for KRAS wild-
type tumours (Baker et al. 2011; Jacobs et al. 2009; Kham-
bata-Ford et al. 2007; Pentheroudakis et al. 2013; Yoshida 
et al. 2013). One study reported no correlation between 
AREG expression and outcome, while results published 
recently revealed that colorectal cancer patients displaying 
increased AREG plasma levels after the first application 
of cetuximab showed a poor clinical outcome (Kuramochi 
et al. 2012; Loupakis et al. 2014).
Regarding gastric cancer, no correlation was found 
between AREG serum levels and the response to cetuxi-
mab in combination with a modified FOLFOX6 regimen 
(Han et al. 2009). However, results published recently by 
our group identified AREG secretion in combination with 
other factors as a positive predictor of cetuximab response 
in gastric cancer cell lines (Kneissl et al. 2012). In the 
present study, we characterized four additional cell lines 
for cetuximab sensitivity and AREG secretion. These lat-
est findings are in line with prior results, as we found all 
three cetuximab-sensitive cell lines—GSU, H111TC and 
MKN7—secreted AREG. Interestingly, GSU and H111TC 
secreted much higher amounts than MKN7, while MKN7 
is far less sensitive to cetuximab than GSU and H111TC. 
We furthermore found AREG secretion to be significantly 
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cetuximab-sensitive cell line MKN1 but not in cetuximab-
resistant Hs746T cells.
For TGFα, results from the published literature have 
been inconsistent. In colorectal cancer cells and cell lines 
from tumours of the head and neck, overexpression and 
secretion of TGFα were associated with cetuximab resist-
ance (Hobor et al. 2014; Saki et al. 2013; Troiani et al. 
2013). However, patient-based data showed a different pic-
ture: in metastatic colorectal cancer patients treated with 
cetuximab, the presence of TGFα positivity correlated with 
a better outcome (Yoshida et al. 2013). In six colorectal 
cancer patients with wild-type KRAS, only serum TGFα 
levels consistently increased during cetuximab treatment, 
but such a consistent effect was not observed for other 
ligands (Mutsaers et al. 2009). In contrast, another study 
found no correlation of TGFα serum levels and clinical 
outcome in KRAS wild-type metastatic colorectal cancer 
patients treated with panitumumab or cetuximab (Taka-
hashi et al. 2014). Moreover, several studies consistently 
found no association between TGFα mRNA expression 
and clinical outcome of cetuximab-based therapies in colo-
rectal cancer patients (Baker et al. 2011; Cushman et al. 
2015; Khambata-Ford et al. 2007; Pentheroudakis et al. 
2013). However, in patients with rectal cancer, TGFα lev-
els, but not EGF levels, increased during cetuximab treat-
ment, and this increase was correlated with T downstaging 
(Debucquoy et al. 2009). In contrast, in patients suffering 
from tumours of the head and neck, there was no correla-
tion between TGFα expression and efficacy of a cetuximab/
bevacizumab regimen, and also TGFα levels significantly 
increased upon treatment (Argiris et al. 2013). In gas-
tric cancer, data are contradictory, as one study associated 
higher TGFα serum levels with a better response to cetuxi-
mab, longer progression-free survival and longer overall 
survival, while another publication reported a correlation 
between low TGFα serum levels and a higher response 
rate to cetuximab in combination with modified FOLFOX6 
(Han et al. 2009; Zhang et al. 2014). In our cell-based sys-
tem, there was no correlation between TGFα secretion sta-
tus and cetuximab sensitivity of the cell lines. However, 
after 8 days of cetuximab treatment, we detected a non-sig-
nificant increase in secreted TGFα levels in the cetuximab-
sensitive cell line MKN1 and the cetuximab-resistant cell 
line Hs746T. Further analyses are needed to clarify the role 
of TGFα in response to cetuximab.
Only a few studies have investigated the association 
between the cetuximab response and HB-EGF expression, 
and the data are inconsistent: HB-EGF expression was pos-
itively correlated with disease control and median progres-
sion-free survival in metastatic colorectal cancer patients 
treated with cetuximab or panitumumab (Yoshida et al. 
2013). Similar to TGFα, there were consistent reports that 
found no significant correlation between HB-EGF mRNA 
expression and clinical outcome parameters in colorectal 
cancer patients treated with cetuximab (Baker et al. 2011; 
Cushman et al. 2015; Khambata-Ford et al. 2007). Further-
more, results obtained in head and neck cancer cells sug-
gest that HB-EGF is a putative resistance factor against 
cetuximab (Hatakeyama et al. 2010).
To our knowledge, only little data are currently available 
regarding the value of HB-EGF as a predictive marker for 
the cetuximab or trastuzumab response in gastric cancer. 
In our study, only HB-EGF, but not AREG or EGF, res-
cued sensitive gastric cancer cell lines from trastuzumab 
and cetuximab treatment. As mentioned above, enhanced 
pHER2 expression has been associated with trastuzumab 
sensitivity in breast cancer cells (Diermeier et al. 2005; 
Dokmanovic et al. 2014). We were able to detect a com-
parable effect in the trastuzumab-sensitive cell line GSU. 
HB-EGF, but not AREG and EGF, blocked this induction 
pHER2 (Y1248) expression by trastuzumab effectively. 
We conclude that in our cell-based system, exogenous HB-
EGF is a potent resistance factor against trastuzumab and 
cetuximab.
A literature search revealed that for most ligands, no 
consistent picture regarding their relationship with the clin-
ical and prognostic features of gastric cancer was present. 
However, regarding different HB-EGF forms, all publica-
tions reported an association with advanced disease (Chung 
et al. 2015; Murayama et al. 2002; Shimura et al. 2012; 
Yasumoto et al. 2011). Additionally, there is evidence that 
HB-EGF is involved in the resistance of gastric tumours 
to chemotherapy, as HB-EGF expression was reported to 
be up-regulated in cisplatin- and 5-FU-resistant tumours 
(Suganuma et al. 2003). These findings were strengthened 
by cell culture-based results revealing cisplatin, 5-FU and 
paclitaxel stimulate HB-EGF secretion of gastric can-
cer cells. In this study, a synergistic antitumour effect 
was found when adding a HB-EGF inhibitor to paclitaxel 
(Sanui et al. 2010).
Based on work studying HB-EGF expression in 
advanced gastric cancer tumours, it is likely that HB-EGF 
contributes to the resistance of gastric tumours to tras-
tuzumab- and cetuximab-based therapeutic approaches. 
The HB-EGF inhibitor CRM197 has been shown to be an 
effective inhibitor in gastric cancer cell lines, and further 
research in this field seems promising (Sanui et al. 2010). 
Moreover, the evaluation of HB-EGF as a prognostic 
marker in gastric cancer patients treated with trastuzumab-
containing regimens should be considered.
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